Taysha Gene Therapies (TSHA)
Taysha Gene Therapies on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
51.2M
Short interest
settlement 2026-10-15
11.6
Days to cover
+0.4 days vs prior
75.5%
Short share of volume
2026-11-02
505
Fails to deliver
settlement 2026-09-08
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TSHA is 51,249,292 shares, down 156,092 shares over the last month. Over the last 48 readings it ranged from 15,670,007 shares (29 November 2024) to 56,847,309 shares (15 January 2026). At the reported average volume of 4.4M shares a day that is 11.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tsha" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 51,249,292 | -6.8% | 4,434,507 | 11.56 |
| 2026-09-30 | 55,020,663 | +7.0% | 4,932,731 | 11.15 |
| 2026-09-15 | 51,405,384 | +9.8% | 2,737,353 | 18.78 |
| 2026-08-31 | 46,800,424 | +0.1% | 2,411,900 | 19.40 |
| 2026-08-14 | 46,738,149 | +0.1% | 2,683,255 | 17.42 |
| 2026-07-31 | 46,691,810 | +3.1% | 2,457,105 | 19.00 |
| 2026-07-15 | 45,292,910 | +9.4% | 3,394,752 | 13.34 |
| 2026-06-30 | 41,397,350 | +6.9% | 5,135,302 | 8.06 |
| 2026-06-15 | 38,727,385 | +7.5% | 2,518,298 | 15.38 |
| 2026-05-29 | 36,014,790 | -1.9% | 2,200,406 | 16.37 |
| 2026-05-15 | 36,701,725 | -8.4% | 2,432,321 | 15.09 |
| 2026-04-30 | 40,051,105 | +2.9% | 2,861,013 | 14.00 |
| 2026-04-15 | 38,915,976 | -7.9% | 2,732,337 | 14.24 |
| 2026-03-31 | 42,272,193 | -8.9% | 3,231,344 | 13.08 |
| 2026-03-13 | 46,392,223 | -6.6% | 2,924,988 | 15.86 |
| 2026-02-27 | 49,687,347 | +1.5% | 2,107,725 | 23.57 |
| 2026-02-13 | 48,961,816 | -12.1% | 2,267,620 | 21.59 |
| 2026-01-30 | 55,693,756 | -2.0% | 2,717,859 | 20.49 |
| 2026-01-15 | 56,847,309 | +1.4% | 2,824,138 | 20.13 |
| 2025-12-31 | 56,034,955 | +15.3% | 3,186,030 | 17.59 |
| 2025-12-15 | 48,586,771 | -0.9% | 3,658,712 | 13.28 |
| 2025-11-28 | 49,035,183 | +2.0% | 3,262,649 | 15.03 |
| 2025-11-14 | 48,083,858 | +8.4% | 4,413,876 | 10.89 |
| 2025-10-31 | 44,369,833 | +5.7% | 3,835,077 | 11.57 |
| 2025-10-15 | 41,975,904 | -15.3% | 17,275,657 | 2.43 |
| 2025-09-30 | 49,551,867 | +14.3% | 4,408,932 | 11.24 |
| 2025-09-15 | 43,357,026 | +6.3% | 4,303,310 | 10.08 |
| 2025-08-29 | 40,775,033 | +12.0% | 2,701,789 | 15.09 |
| 2025-08-15 | 36,406,713 | -4.7% | 2,805,616 | 12.98 |
| 2025-07-31 | 38,208,254 | -13.1% | 2,787,745 | 13.71 |
| 2025-07-15 | 43,962,246 | +10.3% | 2,407,406 | 18.26 |
| 2025-06-30 | 39,852,359 | +19.8% | 3,272,180 | 12.18 |
| 2025-06-13 | 33,272,908 | +4.0% | 4,215,534 | 7.89 |
| 2025-05-30 | 31,979,509 | +21.9% | 5,821,526 | 5.49 |
| 2025-05-15 | 26,236,920 | +0.7% | 4,603,838 | 5.70 |
| 2025-04-30 | 26,060,148 | +12.6% | 2,243,392 | 11.62 |
| 2025-04-15 | 23,148,878 | +7.0% | 1,874,745 | 12.35 |
| 2025-03-31 | 21,631,407 | -14.3% | 2,779,454 | 7.78 |
| 2025-03-14 | 25,248,849 | -1.1% | 1,480,686 | 17.05 |
| 2025-02-28 | 25,530,638 | +1.8% | 1,652,297 | 15.45 |
| 2025-02-14 | 25,087,077 | +4.2% | 2,225,270 | 11.27 |
| 2025-01-31 | 24,081,792 | +0.6% | 2,213,933 | 10.88 |
| 2025-01-15 | 23,947,488 | -7.5% | 2,098,883 | 11.41 |
| 2024-12-31 | 25,878,980 | +18.3% | 2,427,016 | 10.66 |
| 2024-12-13 | 21,884,340 | +39.7% | 4,601,115 | 4.76 |
| 2024-11-29 | 15,670,007 | -0.5% | 6,626,693 | 2.36 |
| 2024-11-15 | 15,754,592 | -10.7% | 9,211,168 | 1.71 |
| 2024-10-31 | 17,637,427 | -14.8% | 1,601,878 | 11.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TSHA volume is 75.5%, up 9.4 points over the last five sessions. Over the last 30 readings it ranged from 35.3% (13 October 2026) to 93.3% (9 October 2026). The latest reading is 11.2 points above the 30-session average of 64.3%, on 687K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 518K | 687K | 75.5% | 0 |
| 2026-10-30 | 351K | 557K | 63.0% | 24 |
| 2026-10-29 | 374K | 619K | 60.5% | 2,300 |
| 2026-10-28 | 1.4M | 1.5M | 89.0% | 0 |
| 2026-10-27 | 792K | 1.1M | 75.1% | 0 |
| 2026-10-26 | 418K | 633K | 66.1% | 5 |
| 2026-10-23 | 563K | 873K | 64.5% | 600 |
| 2026-10-22 | 590K | 1.1M | 55.2% | 32 |
| 2026-10-21 | 653K | 1.3M | 49.1% | 0 |
| 2026-10-20 | 1.6M | 3.1M | 50.8% | 269 |
| 2026-10-19 | 1.4M | 2.0M | 69.6% | 0 |
| 2026-10-16 | 615K | 838K | 73.4% | 37 |
| 2026-10-15 | 1.1M | 2.0M | 57.0% | 4,835 |
| 2026-10-14 | 646K | 1.6M | 40.6% | 47,329 |
| 2026-10-13 | 865K | 2.5M | 35.3% | 42,826 |
| 2026-10-12 | 435K | 605K | 71.9% | 204 |
| 2026-10-09 | 1.7M | 1.8M | 93.3% | 50 |
| 2026-10-08 | 367K | 556K | 65.9% | 5,104 |
| 2026-10-07 | 659K | 843K | 78.2% | 42 |
| 2026-10-06 | 710K | 1.2M | 59.9% | 8,635 |
| 2026-10-05 | 548K | 1.1M | 48.9% | 293 |
| 2026-10-02 | 628K | 1.0M | 61.9% | 85,583 |
| 2026-10-01 | 539K | 778K | 69.2% | 172 |
| 2026-09-30 | 865K | 1.0M | 83.5% | 75 |
| 2026-09-29 | 1.0M | 1.3M | 83.1% | 230 |
| 2026-09-28 | 1.2M | 2.3M | 53.1% | 10,158 |
| 2026-09-25 | 853K | 1.3M | 67.8% | 65 |
| 2026-09-24 | 1.9M | 3.6M | 53.3% | 15 |
| 2026-09-23 | 1.5M | 3.4M | 44.9% | 48 |
| 2026-09-22 | 619K | 893K | 69.3% | 292 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 September 2026, the fails-to-deliver balance in TSHA is 505 shares, up 119 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (2 July 2026) to 614,139 shares (1 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-08 | 505 | $5.60 | $3K |
| 2026-09-04 | 386 | $5.57 | $2K |
| 2026-09-01 | 22 | $5.69 | $125 |
| 2026-08-24 | 394 | $6.09 | $2K |
| 2026-07-20 | 1,868 | $5.96 | $11K |
| 2026-07-14 | 4,410 | $5.38 | $24K |
| 2026-07-07 | 1,506 | $6.38 | $10K |
| 2026-07-02 | 5 | $6.65 | $33 |
| 2026-06-30 | 188,201 | $6.73 | $1.3M |
| 2026-06-29 | 30 | $6.34 | $190 |
| 2026-06-22 | 10,000 | $6.42 | $64K |
| 2026-06-18 | 19 | $6.19 | $118 |
| 2026-06-15 | 17,440 | $5.71 | $100K |
| 2026-06-08 | 25,933 | $5.50 | $143K |
| 2026-06-03 | 816 | $5.69 | $5K |
| 2026-06-02 | 16,072 | $5.97 | $96K |
| 2026-05-29 | 10,037 | $5.92 | $59K |
| 2026-05-28 | 6,313 | $5.75 | $36K |
| 2026-05-26 | 11,484 | $5.49 | $63K |
| 2026-05-22 | 55 | $5.54 | $305 |
| 2026-05-13 | 11 | $6.85 | $75 |
| 2026-05-04 | 5,752 | $6.33 | $36K |
| 2026-04-30 | 10,640 | $6.27 | $67K |
| 2026-04-20 | 200 | $6.43 | $1K |
| 2026-04-01 | 614,139 | $4.47 | $2.7M |
| 2026-03-18 | 478 | $4.57 | $2K |
| 2026-03-09 | 10,657 | $4.57 | $49K |
| 2026-02-23 | 45,117 | $4.70 | $212K |
| 2026-02-19 | 1,548 | $4.65 | $7K |
| 2026-02-10 | 13 | $4.61 | $60 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for TSHA in the last 90 days. The most recent filings are listed below. Latest filing: Nagendran Sukumar (President and Head of R&D) on 2026-07-10.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar | President and Head of R&D | Sell | 200K | $6.24 | $1.2M | 936K |
| 2026-06-01 | Stalfort John A III | Director | Grant | 21K | $0.00 | $0 | 1.2M |
| 2026-06-01 | Sepp-Lorenzino Laura | Director | Grant | 21K | $0.00 | $0 | 127K |
| 2026-06-01 | Long Alison S | Director | Grant | 21K | $0.00 | $0 | 127K |
| 2026-06-01 | Donenberg Phillip B. | Director | Grant | 21K | $0.00 | $0 | 241K |
| 2026-04-10 | Nagendran Sukumar | President and Head of R&D | Sell | 200K | $4.46 | $892K | 1.1M |
| 2026-04-10 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 19K | $1.71 | $33K | 1.3M |
| 2026-02-04 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 2K | $4.52 | $7K | 1.4M |
| 2026-01-26 | Nolan Sean P. | Chief Executive Officer | Sell | 41K | $4.61 | $190K | 2.9M |
| 2026-01-26 | Nagendran Sukumar | President and Head of R&D | Sell | 27K | $4.61 | $124K | 1.3M |
| 2026-01-26 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 24K | $4.61 | $110K | 1.4M |
| 2026-01-23 | Nolan Sean P. | Chief Executive Officer | Sell | 137K | $4.75 | $650K | 2.9M |
| 2026-01-23 | Nagendran Sukumar | President and Head of R&D | Sell | 89K | $4.75 | $423K | 1.3M |
| 2026-01-23 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 79K | $4.75 | $375K | 1.5M |
| 2026-01-12 | Nolan Sean P. | Chief Executive Officer | Grant | 1.0M | $0.00 | $0 | 3.1M |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Grant | 427K | $0.00 | $0 | 1.4M |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Sell | 200K | $4.71 | $942K | 1.0M |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 89K | $1.71 | $152K | 1.2M |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 111K | $0.70 | $78K | 1.1M |
| 2026-01-12 | Alam Kamran | CHIEF FINANCIAL OFFICER | Grant | 359K | $0.00 | $0 | 1.5M |
| 2025-12-01 | Nagendran Sukumar | President and Head of R&D | Sell | 260K | $4.51 | $1.2M | 1.0M |
| 2025-12-01 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 260K | $1.71 | $445K | 1.3M |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Sell | 110K | $4.75 | $523K | 1.0M |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 40K | $1.71 | $68K | 1.1M |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 70K | $0.70 | $49K | 1.1M |
| 2025-09-10 | Nagendran Sukumar | President and Head of R&D | Sell | 200K | $3.23 | $646K | 1.0M |
| 2025-09-10 | Nagendran Sukumar | President and Head of R&D | Exercise or conversion | 41K | $0.70 | $29K | 1.2M |
| 2025-08-21 | Nagendran Sukumar | President and Head of R&D | Sell | 57K | $2.85 | $163K | 1.2M |
| 2025-08-21 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 54K | $2.85 | $155K | 1.2M |
| 2025-06-02 | Sepp-Lorenzino Laura | Director | Grant | 57K | $0.00 | $0 | 106K |
| 2025-06-02 | Long Alison S | Director | Grant | 57K | $0.00 | $0 | 106K |
| 2025-06-02 | Donenberg Phillip B. | Director | Grant | 57K | $0.00 | $0 | 220K |
| 2025-06-02 | Stalfort John A III | Director | Grant | 57K | $0.00 | $0 | 1.2M |
| 2025-05-30 | Manning Paul B | TenPercentOwner | Buy | 750K | $2.75 | $2.1M | 2.8M |
| 2025-03-11 | Alam Kamran | CHIEF FINANCIAL OFFICER | Tax withholding | 30K | $1.69 | $50K | 1.2M |
| 2025-01-02 | Alam Kamran | CHIEF FINANCIAL OFFICER | Grant | 431K | $0.00 | $0 | 1.3M |
| 2025-01-02 | Nagendran Sukumar | President and Head of R&D | Grant | 325K | $0.00 | $0 | 1.2M |
| 2025-01-02 | Nolan Sean P. | Chief Executive Officer | Grant | 893K | $0.00 | $0 | 2.1M |
| 2024-06-27 | Manning Paul B | TenPercentOwner | Buy | 1.3M | $2.25 | $3.0M | 1.3M |
| 2024-05-29 | Sepp-Lorenzino Laura | Director | Grant | 49K | $0.00 | $0 | 49K |
| 2024-05-29 | Donenberg Phillip B. | Director | Grant | 49K | $0.00 | $0 | 163K |
| 2024-05-29 | Long Alison S | Director | Grant | 49K | $0.00 | $0 | 49K |
| 2024-05-29 | Stalfort John A III | Director | Grant | 49K | $0.00 | $0 | 1.1M |
| 2024-02-02 | Alam Kamran | CHIEF FINANCIAL OFFICER | Tax withholding | 1K | $1.51 | $2K | 841K |
| 2024-01-02 | Nolan Sean P. | Chief Executive Officer | Grant | 1.2M | $0.00 | $0 | 1.2M |
| 2024-01-02 | Nagendran Sukumar | President and Head of R&D | Grant | 864K | $0.00 | $0 | 898K |
| 2024-01-02 | Alam Kamran | Chief Financial Officer | Grant | 590K | $0.00 | $0 | 842K |
| 2023-11-17 | Manning Paul B | TenPercentOwner | Buy | 100K | $1.63 | $163K | 16.6M |
| 2023-08-24 | Alam Kamran | Chief Financial Officer | Sell | 33K | $2.33 | $77K | 258K |
| 2023-08-16 | Stalfort John A III | Director | Buy | 389K | $0.90 | $350K | 999K |
| 2023-08-16 | Donenberg Phillip B. | Director | Buy | 111K | $0.90 | $100K | 114K |
| 2023-08-16 | Nolan Sean P. | Chief Executive Officer | Buy | 444K | $0.90 | $400K | 1.5M |
| 2023-08-16 | Stalfort John A III | Director | Gift | 50K | $0.00 | $0 | 1.0M |
| 2023-08-16 | Stalfort John A III | Director | Buy | 389K | $0.90 | $350K | 884K |
| 2023-08-16 | Manning Paul B | TenPercentOwner | Buy | 16.5M | $0.90 | $14.8M | 16.5M |
| 2023-07-13 | Session R.A. II | TenPercentOwner | Sell | 5K | $0.70 | $4K | 8.9M |
| 2023-07-12 | Session R.A. II | TenPercentOwner | Sell | 81K | $0.71 | $57K | 8.9M |
| 2023-06-23 | Session R.A. II | TenPercentOwner | Sell | 18K | $0.70 | $13K | 9.0M |
| 2023-06-22 | Session R.A. II | TenPercentOwner | Sell | 11K | $0.70 | $7K | 9.0M |
| 2023-06-21 | Session R.A. II | TenPercentOwner | Sell | 139K | $0.70 | $97K | 9.0M |
| 2023-06-20 | Session R.A. II | TenPercentOwner | Sell | 296K | $0.71 | $210K | 9.1M |
| 2023-05-31 | Alam Kamran | Chief Financial Officer | Grant | 6K | price not stated in the filing | not stated | 291K |
| 2023-05-16 | Nagendran Sukumar | President and Head of R&D | Buy | 5K | $0.68 | $3K | 34K |
| 2023-03-06 | Session R.A. II | TenPercentOwner | Other transaction | 251K | $0.00 | $0 | 9.4M |
| 2023-02-02 | Alam Kamran | Chief Financial Officer | Grant | 19K | price not stated in the filing | not stated | 285K |
| 2022-10-31 | Manning Paul B | Director,TenPercentOwner | Buy | 1.5M | $2.00 | $3.0M | 1.6M |
| 2022-08-23 | Alam Kamran | Chief Financial Officer | Sell | 3K | $3.47 | $12K | 266K |
| 2022-08-22 | Alam Kamran | Chief Financial Officer | Sell | 10K | $3.50 | $34K | 269K |
| 2022-08-19 | Alam Kamran | Chief Financial Officer | Sell | 11K | $3.75 | $43K | 279K |
| 2022-08-18 | Alam Kamran | Chief Financial Officer | Sell | 7K | $3.87 | $29K | 291K |
| 2022-07-06 | PRASAD SUYASH | CMO and Head of R&D | Sell | 9K | $3.79 | $34K | 531K |
| 2022-07-05 | PRASAD SUYASH | CMO and Head of R&D | Sell | 4K | $3.51 | $14K | 540K |
| 2022-07-01 | PRASAD SUYASH | CMO and Head of R&D | Sell | 24K | $3.53 | $84K | 543K |
| 2022-06-30 | PRASAD SUYASH | CMO and Head of R&D | Sell | 14K | $3.72 | $52K | 567K |
| 2022-06-29 | PRASAD SUYASH | CMO and Head of R&D | Sell | 12K | $3.81 | $47K | 581K |
| 2022-02-03 | Manning Paul B | Director,TenPercentOwner | Buy | 50K | $7.84 | $392K | 142K |
| 2022-02-03 | Manning Paul B | Director,TenPercentOwner | Buy | 27K | $7.84 | $209K | 2.1M |
| 2022-02-02 | Donenberg Phillip B. | Director | Buy | 3K | $7.78 | $23K | 3K |
| 2022-02-02 | Nagendran Sukumar | Director | Buy | 10K | $8.01 | $80K | 29K |
| 2022-02-02 | Manning Paul B | Director,TenPercentOwner | Buy | 45K | $7.77 | $350K | 2.1M |
| 2022-02-02 | Manning Paul B | Director,TenPercentOwner | Buy | 58K | $7.77 | $451K | 92K |
| 2022-02-02 | Manning Paul B | Director,TenPercentOwner | Buy | 22K | $7.77 | $171K | 22K |
| 2021-11-24 | Manning Paul B | Director,TenPercentOwner | Buy | 2K | $13.19 | $29K | 34K |
| 2021-11-23 | Manning Paul B | Director,TenPercentOwner | Buy | 20K | $12.54 | $251K | 32K |
| 2021-11-23 | Session R.A. II | President and CEO | Buy | 26K | $12.65 | $329K | 9.2M |
| 2021-11-23 | Session R.A. II | President and CEO | Buy | 17K | $12.12 | $200K | 9.2M |
| 2021-08-20 | Alam Kamran | Chief Financial Officer | Sell | 10K | $16.70 | $163K | 300K |
| 2021-08-20 | Alam Kamran | Chief Financial Officer | Sell | 2K | $17.14 | $36K | 298K |
| 2021-08-19 | Alam Kamran | Chief Financial Officer | Sell | 613 | $17.11 | $10K | 310K |
| 2021-08-19 | Alam Kamran | Chief Financial Officer | Sell | 9K | $16.43 | $154K | 311K |
| 2021-08-18 | Alam Kamran | Chief Financial Officer | Sell | 11K | $17.35 | $194K | 320K |
| 2021-07-01 | PRASAD SUYASH | CMO and Head of R&D | Sell | 20K | $21.12 | $416K | 594K |
| 2021-06-30 | PRASAD SUYASH | CMO and Head of R&D | Sell | 13K | $21.42 | $286K | 620K |
| 2021-06-30 | PRASAD SUYASH | CMO and Head of R&D | Sell | 6K | $22.44 | $139K | 614K |
| 2021-06-30 | PRASAD SUYASH | CMO and Head of R&D | Sell | 500 | $23.70 | $12K | 613K |
| 2021-06-29 | PRASAD SUYASH | CMO and Head of R&D | Sell | 300 | $25.19 | $8K | 633K |
| 2021-06-29 | PRASAD SUYASH | CMO and Head of R&D | Sell | 4K | $24.46 | $94K | 634K |
| 2021-06-29 | PRASAD SUYASH | CMO and Head of R&D | Sell | 35K | $23.74 | $832K | 638K |
| 2021-05-20 | Nolan Sean P. | Director | Buy | 1K | $22.35 | $26K | 1K |
| 2021-05-14 | Manning Paul B | Director,TenPercentOwner | Buy | 12K | $20.98 | $252K | 12K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON18 Form 144 notices on file for TSHA worth $7.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Nagendran Sukumar filed on 2026-07-10 to sell 200,000 shares ($1.3M) from 2026-07-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran SukumarOfficer | 200K | $1.3M | 0.062% | 2026-07-10 | Jefferies LLC |
| 2026-04-10 | Nagendran SukumarOfficer | 200K | $926K | 0.070% | 2026-04-10 | Jefferies LLC |
| 2026-02-27 | Rumana Haque-AhmedOfficer | 2K | $11K | 0.001% | 2026-02-27 | Maxim Group LLC |
| 2026-02-04 | Fred PorterAffiliate-Chief of Staff &amp;amp; Tech.Op.Officer | 889 | $4K | 0.000% | 2026-02-04 | Maxim Group LLC |
| 2026-02-04 | Emily McGinnisAffiliate-Chief Pat. Adv. &amp;amp; Ext. Aff. Off. | 901 | $4K | 0.000% | 2026-02-04 | Maxim Group LLC |
| 2026-02-04 | Sean McAuliffeAffiliate - Chief Business Officer | 914 | $4K | 0.000% | 2026-02-04 | Maxim Group LLC |
| 2026-02-04 | Rumana Haque-AhmedOfficer | 697 | $3K | 0.000% | 2026-02-04 | Maxim Group LLC |
| 2026-02-04 | Kamran AlamOfficer | 2K | $8K | 0.001% | 2026-02-04 | Maxim Group LLC |
| 2026-01-23 | Fred PorterAffiliate-Chief of Staff &amp;amp; Tech.Op.Officer | 55K | $280K | 0.020% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Sean P. NolanOfficer, Director | 168K | $856K | 0.061% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Sukumar NagendranOfficer | 114K | $579K | 0.042% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Emily McGinnisAffiliate-Chief Pat. Adv. &amp;amp; Ext. Aff. Off. | 32K | $163K | 0.012% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Sean McAuliffeAffiliate - Chief Business Officer | 46K | $234K | 0.017% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Rumana Haque-AhmedOfficer | 30K | $153K | 0.011% | 2026-01-23 | Maxim Group LLC |
| 2026-01-23 | Kamran AlamOfficer | 101K | $513K | 0.037% | 2026-01-23 | Maxim Group LLC |
| 2026-01-12 | Nagendran SukumarOfficer | 200K | $996K | 0.073% | 2026-01-12 | Jefferies LLC |
| 2025-11-28 | Nagendran SukumarOfficer | 370K | $1.8M | 0.135% | 2025-11-28 | Jefferies LLC |
| 2025-09-22 | Rumana Haque-AhmedOfficer | 11K | $30K | 0.004% | 2025-09-22 | Maxim Group LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of TSHA in their latest filing, all on Schedule 13G (passive). The largest reported stake is RA Capital Management, L.P. at 9.9% of the class (32,886,242 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 5 | RA Capital Management, L.P.investment adviser, partnership | 32.9M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Peter Kolchinskyparent holding company, individual | 32.9M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | Rajeev Shahparent holding company, individual | 32.9M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 5 | RA Capital Healthcare Fund, L.P.partnership | 32.9M | 9.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 2 | Morgan Stanleyparent holding company, corporation | 16.2M | 5.1% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 2 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 16.0M | 5.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 5 | Roderick Wongparent holding company, individual | 20.7M | 7.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | RTW Investments, LPinvestment adviser, partnership | 20.7M | 7.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Ryan Wilderparent holding company, individual | 18.0M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Vestal Point Capital, LPinvestment adviser, partnership | 18.0M | 6.3% | 2026-03-31 |
| 2026-02-05 | 13G/Ano. 10 | FMR LLCparent holding company | 13.5M | 4.9% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 10 | Abigail P. Johnsonindividual | 13.5M | 4.9% | 2025-12-31 |
| 2026-01-21 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 17.9M | 6.5% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Octagon Investments Master Fundpartnership, other entity | 9.1M | 3.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Ting Jiaparent holding company, individual | 9.1M | 3.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Octagon Capital Advisors LPinvestment adviser, partnership | 9.1M | 3.3% | 2025-09-30 |
13F holders
Tracked managers holding TSHA at their latest 13F. JSON5 of the 30 tracked managers held TSHA at their latest 13F, $57.4M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $30.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 4.4M | $30.0M | 0.01% | -29K |
| Millennium Management | 2026-06-30 | 2.1M | $14.5M | 0.01% | -1.2M |
| Citadel Advisors | 2026-06-30 | 1.5M | $10.5M | 0.00% | +1.1M |
| Two Sigma Investments | 2026-06-30 | 235K | $1.6M | 0.00% | -507K |
| AQR Capital Management | 2026-06-30 | 129K | $877K | 0.00% | -49K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Taysha Gene Therapies in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Taysha Gene Therapies (TSHA), SEC CIK 1806310, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-10.JSON and CSV
- Company record
- EDGAR filing index for CIK 1806310Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of TSHA is sold short?
51,249,292 shares were held short at the 2026-10-15 settlement, 11.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TSHA's daily short volume?
On 2026-11-02, 518,400 of the 686,876 TSHA shares reported to FINRA were sold short, 75.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TSHA have fails to deliver?
The SEC's latest file shows 505 TSHA shares failed to deliver at settlement 2026-09-08. Fails are reported per settlement date and published twice a month with a lag.
Are TSHA insiders buying or selling?
No open-market insider trades were reported for TSHA in the last 90 days. The most recent filings are listed below. Latest filing: Nagendran Sukumar (President and Head of R&D) on 2026-07-10.
Have TSHA insiders filed to sell?
18 Form 144 notices on file for TSHA worth $7.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Nagendran Sukumar filed on 2026-07-10 to sell 200,000 shares ($1.3M) from 2026-07-10.
Who owns 5% or more of TSHA?
11 holders report 5% or more of TSHA in their latest filing, all on Schedule 13G (passive). The largest reported stake is RA Capital Management, L.P. at 9.9% of the class (32,886,242 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own TSHA?
5 of the 30 tracked 13F managers held TSHA shares at their latest filing, $57.4M in all. The largest: D. E. Shaw & Co. (4.4M shares, $30.0M), Izzy Englander's Millennium Management (2.1M shares, $14.5M), Ken Griffin's Citadel Advisors (1.5M shares, $10.5M), Two Sigma Investments (235K shares, $1.6M), Cliff Asness's AQR Capital Management (129K shares, $877K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.